Sustained Lung Inflation in Preterm Infants

June 7, 2020 updated by: Douaa El Saied El Sherbiny, Kasr El Aini Hospital

Effect of Application of Sustained Lung Inflation on the Respiratory Outcome of Preterm Infants With Respiratory Distress Syndrome

This is a randomized controlled study to investigate the effect of application of sustained lung inflation (SLI) at birth on the respiratory outcome of preterm infants with respiratory distress syndrome.

Study Overview

Detailed Description

Enrolled infants (n=160) were randomized before birth into 2 groups (intervention and control group) in a ratio 1:1. Randomization was done through an online randomizer (www.graphpad.com), and sealed envelopes were used to assign the infant to one of the two groups.

Study Type

Interventional

Enrollment (Actual)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt
        • Kasralainy Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 1 minute (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Gestational age ≥ 27 weeks and ≤ 32 weeks
  • Appropriate for gestational age
  • Weight >800 grams

Exclusion Criteria:

  • Major congenital anomalies (congenital heart, cerebral, lung or abdominal malformations)
  • Fetal hydrops

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sustained lung inflation

Participants in this arm (n=80) received:

  1. Sustained lung inflation (SLI) manoeuvre(s) was applied once or twice, based on the protocol algorithm.

    Within the first 60 seconds of life, assessment for the need of advanced resuscitation (defined as the need for more than oxygen and tactile stimulation during resuscitation) was done;

    • Infants who needed advanced resuscitation were considered to receive SLI as a rescue approach.
    • Infants who needed only oxygen and tactile stimulation were considered to receive SLI as a prophylactic approach.
  2. Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed.
SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device
CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
Other: Control

Participants in this arm (n=80) received:

  1. Resuscitation according to the American academy of pediatrics guidelines.
  2. Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed.
CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Need for invasive mechanical ventilation or death
Time Frame: From birth up to 72 hours of life
Treatment failure; defined as the need for intubation and invasive mechanical ventilation or death
From birth up to 72 hours of life

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of invasive mechanical ventilation
Time Frame: From date of birth until the date of discharge home or death from any cause, whichever came first, assessed upto 100 days
The duration of intubation and invasive mechanical ventilation (in days)
From date of birth until the date of discharge home or death from any cause, whichever came first, assessed upto 100 days
Pneumothorax
Time Frame: From date of birth until the date of discharge home or death from any cause, whichever came first, assessed upto 100 days
Pneumothorax, documented by radiological findings
From date of birth until the date of discharge home or death from any cause, whichever came first, assessed upto 100 days
Bronchopulmonary dysplasia
Time Frame: Assessed at 36 weeks postmenstrual age or discharge, whichever came first
Bronchopulmonary dysplasia, defined as the need for more than 21% oxygen for at least 28 days
Assessed at 36 weeks postmenstrual age or discharge, whichever came first

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 21, 2014

Primary Completion (Actual)

January 18, 2017

Study Completion (Actual)

September 5, 2017

Study Registration Dates

First Submitted

April 12, 2018

First Submitted That Met QC Criteria

May 7, 2018

First Posted (Actual)

May 8, 2018

Study Record Updates

Last Update Posted (Actual)

June 9, 2020

Last Update Submitted That Met QC Criteria

June 7, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 75381

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preterm Infant

Clinical Trials on Sustained lung inflation (SLI)

3
Subscribe